Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397696 · ClinicalTrials.gov registry record · Phase 2
Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease
A Phase 2 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00397696 is a Phase 2 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 9 participants.
The verdict
NCT00397696, a Phase 2 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The underlying goal of this study is to assess \[123I\] 5-IA and SPECT imaging as a tool to detect nicotinic receptor activity in the brain of PD patients. All study procedures will be conducted at the Institute for Neurodegenerative Disorders (IND) and Molecular NeuroImaging (MNI) in New Haven, CT. Approximately 10 patients with a diagnosis of PD without cognitive changes will be recruited to participate in this study. Patients will be eligible to participate if they have a diagnosis of PD of more than 2 years duration and have no significant cognitive changes.
Interventions
- DRUG [123I] 5-IA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00397696
The ClinicalTrials.gov registry entry for NCT00397696 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [123I] 5-IA is the first listed.
NCT00397696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00397696 about?
NCT00397696 is a clinical study titled "Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease". The underlying goal of this study is to assess \[123I\] 5-IA and SPECT imaging as a tool to detect nicotinic receptor activity in the brain of PD patients. All study procedures will be conducted at the Institute for Neurodegenerative Disorders (IND) and Molecular NeuroImaging (MNI) in New Haven, CT....
What is the current status of trial NCT00397696?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2006-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00397696?
The interventions under investigation include: [123I] 5-IA (DRUG).
Who is sponsoring clinical trial NCT00397696?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.